Effect of a mechanical vs a pharmacologic increase in aortic pressure on coronary blood flow and thrombolysis induced by IV administration of a thrombolytic agent

Chest

Volumn 111, Issue 2, 1997, Pages 449-453

  Prewitt, Richard M ^a   Gu, Shian ^a   Schick, Usha ^a   Ducas, John ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

aortic pressure; recombinant tissue plasminogen activator; thrombolytic therapy

Indexed keywords

ALTEPLASE; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA PRESSURE; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY THROMBOSIS; DOG; FOGARTY CATHETER; HEART OUTPUT; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PHLEBOTOMY; PRIORITY JOURNAL;

EID: 0031027928     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.111.2.449     Document Type: Article

References (13)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1:397-401
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2(No. 8607):349-60
3. Bates ER, Topol EJ. Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol 1991; 18:1077-84
4. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76:142-54
5. Carney RJ, Murphy GA, Brandt TR, et al. Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. J Am Coll Cardiol 1992; 20:17-23
6. Hsia J, Hamilton WP, Kleiman N, et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323:1433-47
7. Bleich SD, Nichols TC, Schumacher RR, et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66:1412-17
8. Prewitt RM, Gu S, Garber PJ, et al. Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992; 20:1626-33
9. 99mTC sulfur colloid. Radiology 1983; 146:185-89
10. 99mTC colloid by intravascular clot. Br J Radiol 1976; 49:803-04
11. Garber PJ, Gu S, Ducas J, et al. An increase in low aortic pressure increases coronary artery flow and coronary thrombolysis induced by intravenous administration of recombinant tissue plasminogen activator. J Crit Care 1995; 10:1-6
12. Prewitt RM, Gu S, Schick U, et al. Intraaortic balloon counterpulsation enhances coronary thrombolysis induced by intravenous administration of a thrombolytic agent. J Am Coll Cardiol 1994; 23:794-98
13. Kennedy JW, Gensini GG, Timmis GC, et al. Acute myocardial infarction treated with intracoronary streptokinase: a report of the Society for Cardiac Angiography. Am J Cardiol 1985; 55:871-77